Glaukos Announces Participation in 30th Annual ROTH Conference
March 02 2018 - 7:00AM
Business Wire
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical
technology company focused on the development and commercialization
of breakthrough products and procedures designed to transform the
treatment of glaucoma, today announced that its management is
scheduled to participate in the 30th Annual ROTH Conference on
Monday, March 12, 2018, at 10:00 a.m. PDT in Laguna Niguel,
California.
A live audio webcast for this event will be available in the
Investors section of the Glaukos website at
http://investors.glaukos.com and will be archived for 90 days.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology
company focused on the development and commercialization of
breakthrough products and procedures designed to transform the
treatment of glaucoma, one of the world’s leading causes of
blindness. The company pioneered Micro-Invasive Glaucoma Surgery,
or MIGS, to revolutionize the traditional glaucoma treatment and
management paradigm. Glaukos launched the iStent®, its first MIGS
device, in the United States in July 2012 and is leveraging its
platform technology to build a comprehensive and proprietary
portfolio of micro-scale injectable therapies designed to address
the complete range of glaucoma disease states and progression. The
company believes the iStent, measuring 1.0 mm long and 0.33 mm
wide, is the smallest medical device ever approved by the FDA.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180302005037/en/
Glaukos CorporationChris LewisDirector, Investor Relations,
Corporate Strategy &
Development949-481-0510clewis@glaukos.com
Glaukos (NYSE:GKOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Glaukos (NYSE:GKOS)
Historical Stock Chart
From Apr 2023 to Apr 2024